Intervention

A

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting0

Common conditions8

Lead sponsors shown4

Clinical trials

5 shown

A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCCNCT04215003 · 2020-01-20

Effect of Targeting Left Ventricular Lead Position on the Rate of Response to Cardiac Resynchronization Therapy.NCT00399594 · 2011-03-01

Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.NCT01424462 · 2010-04-19

Optimal Programming to Improve Mechanical Indices, Symptoms and Exercise in Cardiac Resynchronization Therapy.NCT00489177 · 2007-06-01

Moderate Alcohol Consumption, Fat and Carbohydrate Metabolism and Insulin SensitivityNCT00364767 · 2004-10-01

Common conditions

Breast Cancer1 Cardiac Pacing, Artificial1 Cardiovascular Disease1 Defibrillators1 Diabetes Mellitus, Type 21 Heart Failure1 Heart Failure, Congestive1 Multiple Sclerosis, Relapsing-Remitting1

Leading sponsors

University of Calgary2 Fudan University1 GlaxoSmithKline1 TNO1

Trial status mix

COMPLETED4

UNKNOWN1

Phase mix

PHASE12

PHASE22

NA1

PHASE31

PHASE41

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.